JP, M., C, L., S, C., S, P., M, S., N, S., . . . J, M. (2023). Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Citación estilo ChicagoJP, Muñoz, et al. Early Salvage Chemo-Immunotherapy With Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients With Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes. 2023.
Cita MLAJP, Muñoz, et al. Early Salvage Chemo-Immunotherapy With Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients With Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes. 2023.